^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
European Commission Approves Expanded Indication for Merck’s KEYTRUDA (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Published date:
03/17/2021
Excerpt:
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult and pediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma (cHL)...This approval is the first pediatric approval for KEYTRUDA in the European Union (EU).
Source:
Published date:
07/17/2015
Excerpt:
Keytruda as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.
Source:
Excerpt:
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult patients with relapsed or refractory cHL….for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
Source:
Published date:
10/12/2023
Excerpt:
Hodgkin Lymphoma: PRINCIPLES OF SYSTEMIC THERAPY...Pembrolizumab + ICE…
Secondary therapy:
ICE
Source:
Published date:
11/19/2021
Excerpt:
Hodgkin Lymphoma: PRINCIPLE OF SYSTEMIC THERAPY... RELAPSED OR REFRACTORY DISEASE...Second-Line and subsequent Therapy...CHL...GVD + pembrolizumab
Source:
Published date:
12/14/2020
Excerpt:
Hodgkin Lymphoma: CHL, Second-line option added: Pembrolizumab...
Source:
Excerpt:
Pediatric Hodgkin Lymphoma: Subsequent Therapy Options...Pembrolizumab
Source:
Title:
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
Published date:
03/12/2021
Excerpt:
After a median time from randomisation to data cutoff of 25·7 months...median progression-free survival was 13·2 months...for pembrolizumab versus 8·3 months (5·7–8·8) for brentuximab vedotin....Pembrolizumab showed statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin....
DOI:
https://doi.org/10.1016/S1470-2045(21)00005-X
Trial ID:
Source:
Title:
Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Published date:
02/01/2021
Excerpt:
Merck (NYSE: MRK)...today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy. The opinion is recommending KEYTRUDA as monotherapy for the treatment of adult and pediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma (cHL)...Opinion Granted Based on Significant Progression-Free Survival Benefit Demonstrated With KEYTRUDA Monotherapy Compared to Brentuximab Vedotin in Pivotal Phase 3 KEYNOTE-204 Trial
Source:
Title:
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL)
Excerpt:
In pts with R/R cHL, pembro was superior to BV and demonstrated statistically significant and clinically meaningful improvement in PFS across all subgroups, with safety consistent with previous reports. Pembro monotherapy should be standard of care for this pt population with R/R/cHL.
DOI:
10.1200/JCO.2020.38.15_suppl.8005
Trial ID:
